Ionis Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing also reports unaudited fourth-quarter results for the three months ended December 31, 2023. Ionis is an RNA-targeted medicines company with five marketed medicines and nine medicines in registration or Phase 3 development.
Business Context and Key Developments
- Marketed medicines are SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA.
- FDA approvals in 2023 included QALSODY for SOD1-ALS in April and WAINUA for ATTRv-PN in December. WAINUA launched in the U.S. in January 2024 with AstraZeneca.
- Ionis reported positive late-stage data for WAINUA, olezarsen and donidalorsen, advanced zilganersen, ulefnersen, bepirovirsen and IONIS-FB-L Rx programs, and initiated the Phase 1/2 study of ION717.
- Ionis remains substantially dependent on collaboration and royalty revenue, particularly from Biogen, AstraZeneca, Roche, Novartis, GSK and Otsuka.
Financial Performance
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $787.6 million | $587.4 million | +34% |
| Commercial revenue | $308.6 million | $303.4 million | +2% |
| R&D revenue | $479.1 million | $284.0 million | +69% |
| Operating expenses | $1,141.4 million | $997.6 million | +14% |
| Loss from operations | $(353.7) million | $(410.2) million | Improved |
| Net loss | $(366.3) million | $(269.7) million | Worsened |
| Basic and diluted loss per share | $(2.56) | $(1.90) | Worsened |
| Operating cash flow | $(307.5) million | $(274.4) million | More cash used |
| Cash, cash equivalents and short-term investments | $2.331 billion | $1.987 billion | +17% |
- Commercial revenue included $240.4 million of SPINRAZA royalties, $34.9 million from TEGSEDI and WAYLIVRA, and $33.3 million of licensing and other royalty revenue, including QALSODY royalties.
- R&D revenue benefited from collaboration payments, including a $50 million WAINUA approval milestone from AstraZeneca, a $36 million ION826 license payment, and payments from Otsuka, Roche and Novartis.
- Operating margin was approximately negative 44.9%; net margin was approximately negative 46.5%.
- Research, development and patent expense increased to $899.6 million from $833.1 million, principally because late-stage programs advanced and Phase 3 studies became fully or nearly fully enrolled.
- SG&A increased to $232.6 million from $150.3 million due to commercial launch preparation. The 2023 results included a $20 million charge related to termination of a build-to-suit lease.
- Investment income increased to $89.0 million from $25.3 million due to higher interest rates and higher invested balances.
Liquidity, Cash Flow and Debt
- Ionis ended 2023 with $399.3 million of cash and cash equivalents and $1.932 billion of short-term investments.
- Operating activities used $307.5 million of cash, while investing activities used $214.1 million. Financing activities provided $644.1 million.
- Ionis issued $575 million of 1.75% convertible senior notes due June 2028 and used approximately $488.2 million of proceeds to repurchase $504.4 million principal amount of 0.125% notes due December 2024.
- Outstanding convertible notes at year-end included $575 million of 1.75% notes, $632.5 million of 0% notes due April 2026 and approximately $44.5 million of 0.125% notes due December 2024.
- Ionis received $500 million from Royalty Pharma in exchange for a portion of future SPINRAZA and pelacarsen royalties and recorded a $513.7 million net liability at year-end. The arrangement generated $68.8 million of related interest expense in 2023.
- Total contractual obligations, excluding the royalty monetization liability, were approximately $1.588 billion, including debt, leases, mortgage payments and other obligations.
- Management stated that existing cash, investments and expected future cash flows should be sufficient to fund planned operations and obligations, but additional funding could be required if commercialization or partnering objectives are not achieved.
Material Changes Versus 2022
- Revenue increased substantially, but the increase was driven primarily by collaboration, milestone and license revenue rather than commercial product growth.
- Commercial revenue was broadly stable, while SPINRAZA royalties declined slightly from $242.3 million to $240.4 million.
- Operating loss improved because 2022 included an $80 million Metagenomi licensing charge and a $150.1 million real-estate gain; however, net loss increased in 2023 due to higher operating spending, royalty-sale interest expense and income taxes.
- Ionis expanded its debt and royalty-related obligations but also increased liquidity through the Royalty Pharma transaction and the 1.75% notes issuance.
- Ionis entered into new collaborations with Novartis and Roche and licensed European donidalorsen commercialization rights to Otsuka for a $65 million upfront payment.
- The North American TEGSEDI distribution agreement with Sobi was terminated in October 2023. Ionis began transitioning responsibilities internally and initiated the process to withdraw the TEGSEDI NDA in February 2024.
Outlook, Commentary and Risks
- Management is prioritizing commercialization of WAINUA and preparing for potential U.S. launches of olezarsen and donidalorsen while continuing investment in its late-stage pipeline and technology platforms.
- Ionis expected to file U.S. and European applications for olezarsen in FCS during 2024 and a U.S. NDA for donidalorsen during 2024. These are targets, not guarantees.
- WAINUA’s Phase 3 CARDIO-TTRansform study completed enrollment, with data expected as early as 2025.
- QALSODY has accelerated approval; continued approval depends on confirmation of clinical benefit in required confirmatory studies.
- Key risks include clinical or regulatory failure, adverse safety findings, manufacturing and supply constraints, payer coverage and pricing pressure, competition, dependence on partners, intellectual-property challenges, and the company’s limited history of direct commercialization.
- Royalty Pharma payments and the related liability depend materially on future SPINRAZA sales and regulatory approval and sales of pelacarsen. The filing states that these estimates are particularly subjective for pelacarsen.
- Ionis reported no pending material legal proceedings. Management and Ernst & Young concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2023.
Most Important Facts for Investors to Verify
- Whether WAINUA achieves meaningful U.S. commercial adoption and generates royalties and direct commercial revenue as planned.
- Timing, regulatory outcomes and launch economics for olezarsen and donidalorsen, including payer coverage and competitive positioning.
- Progress and results of the CARDIO-TTRansform, pelacarsen, bepirovirsen, IONIS-FB-L Rx and other Phase 3 programs.
- SPINRAZA royalty trends, competitive pressure from gene therapy and oral alternatives, and the portion of royalties payable to Royalty Pharma.
- Ability to reduce operating cash burn while funding clinical development and commercialization activities.
- Refinancing or settlement of the remaining 0.125% notes due December 2024 and the 0% notes due April 2026.
- Potential dilution from convertible notes, warrants, equity compensation and approximately 28.2 million shares issuable upon conversion of specified notes.
- Assumptions supporting the $513.7 million royalty-sale liability, including pelacarsen approval probability, market penetration and projected royalty payments.